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Diagnosis and management of vertebral metastasis requires a systematic approach to patient identiﬁcation as well as selection of
appropriatetherapy.Rapididentiﬁcationandpromptinterventioninthetreatmentofmalignantepiduralspinalcordcompression
(MESCC) is key to maintaining quality of life. This paper provides a series of tools as well as guidance in selecting eﬀective and
evidence-based therapy individualized to the speciﬁc patient.
1.Introduction
Managing vertebral metastasis is a common problem in
modern oncology. It is also a great deal more complicated
than it would ﬁrst appear. The problem spans the extremes
of modern oncologic management from simple palliation
to the newly recognized situation of “oligometastasis” which
implies the potential for durable remission. The last twenty
years have seen the introduction of advanced imaging which
has greatly expanded our ability to detect and quantify this
disease noninvasively. The last ten years introduced a syste-
maticandever-increasingbodyofknowledge,aswellastech-
niques, which have increased our ability to oﬀer meaningful
intervention. The purpose of this paper is to outline a logical
and evidence-based approach to the diagnosis and manage-
ment of vertebral metastasis. Choosing wisely among the
many options will provide optimum outcome for patients in
a cost-eﬀective manner.
Amongthemostpotentiallydevastatingcomplicationsof
metastatic cancer is malignant epidural spinal cord compres-
sion (MESCC), and so, that seems a logical place to start.
MESCC is an oncologic emergency that lies hidden among
the forest of simple vertebral metastasis. Prompt recognition
and appropriate intervention has a profound impact on
patient quality of life as well as overall survival. Maintaining
optimal sensory and motor function is imperative. As such,
clinicians need to be aware of this entity and have a logical
approach to its evaluation and management. Any patient
with a history of malignant disease who presents with back
pain or any focal neurologic deﬁcit should be evaluated
urgently for the possibility of MESCC.
2. DiagnosticEvaluationof MESCC
As always, a careful history and physical examination is
indicated. Unfortunately, the history and physical examina-
tion does not appear to be suﬃciently sensitive to stratify
patients who need deﬁnitive imaging evaluation [1, 2]. A
history of cancer, especially when it is known or suspected
to be metastatic, should raise the possibility of MESCC
especially when it is combined with any focal neurologic
deﬁcit. Pain, although common, is not a requirement in the
setting of MESCC [3]. Pain can be localized to the spine or
it may be radicular in nature. Frequently, patients may be on
analgesics which could mask the pain as well as contribute
to constipation or urinary hesitancy. Both constipation and
urinary hesitancy can be signs of MESCC as well.
Focal ﬁndings of weakness should always raise the con-
cernofMESCCinapatientwithcancer,butlikepain,itisnot
arequirementofthediagnosis[1].Acarefulneurologicexam
may often assist in localizing a level of the cord that is clin-
ically suspicious for cord compression. Although the history2 ISRN Surgery
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andphysicalexaminationareimportant,theycannotreliably
identify those patients who are not at risk of MESCC [1].
Deﬁnitiveimagingobtainedinanurgentmannerisrequired.
The modern gold standard for the imaging evaluation
of MESCC is MRI of the entire spine [4]. Although simpler
and less expensive imaging has been advocated in the past
prior to requesting an MRI, these imaging tests have not
demonstrated any signiﬁcant ability to abrogate the need for
MRI. They only delay the deﬁnitive imaging study and, so,
they should be avoided when clinical suspicion of MESCC
is raised. However, once MESCC has been ruled out, further
imaging and other clinical parameters can have a signiﬁcant
impact on patient management and should be integrated
into the evaluation and management process [3].
In the rare situation in which MRI is either not available
or not safe for a particular patient, the other acceptable
imaging study is myelography. Although some authors con-
sider this potentially more sensitive than MRI, the diﬀerence
in detection is likely conﬁned to subtle and early lesions.
This potential advantage is oﬀset by the invasive nature of
the study. When performed, the initial study is usually a
lumbar myelogram. In the situation where a complete block
to CSF ﬂow occurs, it is necessary to supplement the study
with a cervical myelogram to accurately assess the extent ofISRN Surgery 3
involvementasupto30%ofMESCCcanhavemultiplelevels
involved [4].
3. Management of MESCC
Once MESCC has been diagnosed, prompt management of
the disease is necessary for optimal patient outcome. The
ﬁrst step is to initiate management with steroids in patients
who have focal neurologic deﬁcit [5]. Optimal steroid
management is a subject of signiﬁcant debate. Although
there is some evidence in support of high dose steroids [6],
there is also a concomitant increase in the observed serious
consequences of their use. Since many of these patients will
come to the attention of spine surgeons, it would be prudent
tounderstandandfollowaninstitutionalprotocolforsteroid
management that has been developed in consultation with
the surgical service involved.
Traditionally, MESCC has been a disease managed with
radiotherapy. More recently, a multi-institution phase III
trial by Patchel et al. has established a role for surgery in the
management of this disease [7]. It is important to bear in
mind that the patients in this study all had MESCC which
was deﬁned, at a minimum, by displacement of the cord
by mass within the spinal canal. It is also important to
keep in mind that the surgery performed was a maximal
safe debulking of the tumor and not a simple posterior
laminectomy. This study was halted early when an interim
evaluation met the predetermined stopping criteria. Patients
who received surgery as a component of their therapy had
b o t hap r o l o n g a t i o no fs u r v i v a la sw e l la sp r e s e r v a t i o no f
ability to walk. In this study, surgery was combined with
postoperativeradiotherapywhenthepatientshadadequately
healed.Surgicalintervention inthispatientpopulation isnot
onlyeﬀectiveatpreservingambulatorystatus,butalsoacost-
eﬀective treatment [8].
One of the main disadvantages to the surgical treatment
of MESCC as advocated by Patchel is the extent of surgery
many patients require. It is diﬃcult to justify the risks of
surgical treatment if the patient does not have a signiﬁcant
life expectancy. Until recently, it has been diﬃcult to separate
out disparate classes of patients with MESCC especially with
respect to life expectancy. In 2008, Rades et al. published
the results of an international retrospective review of over
2000 patients treated for MESCC with radiotherapy only [9].
Based upon this information, they were able to construct a
scoringsystemthataccuratelypredictsbothpatientlongevity
as well as the ability of radiation to preserve ambulatory sta-
tus.Thisscoringsystemhassubsequentlybeenvalidatedona
separatepatientpopulation[10].Radesetal.’sworkampliﬁes
the pioneering work of Patchel by identifying patients who
are likely to be candidates for surgical intervention. Patients
in Group A have such limited life expectancy that rapid
palliative measures make the most sense, while patients
in Group E are quite well served by the use of radiation
alone. Groups B, C, and D represent those patients whose
life expectancy is long enough that ambulation is a serious
concern and radiation alone does not adequately address this
(see Figures 1, 2,a n d3).
The nonsurgical management of MESCC, as demon-
strated in the article by Rades et al. [9], can be eﬀective
in the long-term management of this disease. Standard
radiotherapy can be eﬀective in the palliation of both pain
and neurologic dysfunction, and there is no clearly superior
regimen in addressing the acute symptoms.
Until recently, it has been unclear whether neurologic
function, speciﬁcally ambulation, is adequately addressed
with a single-fraction treatment course. Recent prospective
randomized trials have demonstrated that, in fact, single-
fraction radiation is equally as eﬀective as more protracted
courses with regard to ambulation [11–13]. There is, how-
ever, a suggestion that patients who have a longer predicted
survival may have less progression or recurrence of MESCC
with courses of 3Gy × 10 or longer [12]. So, for patients
whose Rades score places them in Group E, a more pro-
tractedcourseormoreaggressivetherapymightbeindicated.
The radiotherapeutic options continue to increase with
the recent introduction of stereotactic body radiotherapy
(SBRT) [14]. This new technique builds upon the long
history of MESCC as a disease amenable to radiation
treatment. Often, SBRT is delivered as a single fraction of
radiation as well, but the dose is substantially higher than
8Gy and would be myelopathic if delivered to the spinal cord
[15].Becauseofthepotentialdangerinvolved,thistechnique
must be delivered in a meticulous manner in a program
which meets the quality assurance process as outlined in
the ASTRO/ACR guidelines [16]. When done appropriately,
80%–90% permanent local control can be achieved without
myelopathic injury even in patients with metastases known
to be resistant to conventional doses of radiation [15]. This
form of radiation treatment is substantially more expensive
than conventional radiation and can only be delivered at
select centers. The extent to which SBRT plays a role in the
management of MESCC is still undeﬁned.
4. Followup of Patients Treated for MESCC
Once patients have been successfully managed for MESCC,
they are at increased risk for developing either a relapse of
MESCC or recurrence of the process at a diﬀerent site. This
is especially true for patients who suﬀer from hormone-
resistant prostate cancer. Risk stratiﬁcation of patients in
this situation was published by investigators at the Princess
Margaret hospital, and based upon their ﬁndings, they make
some suggestions on repeat imaging [3]. For patients with
rapidly progressing disease, imaging as frequently as every 4
months might be necessary. More slowly progressive disease
could be followed at yearly intervals. These ﬁndings have
been corroborated by others [17, 18]. It remains to be seen
if similar recommendations can be made for other slowly
progressive systemic cancers. It appears prudent that orderly
followup should be done in order to intercede before the
situation becomes an emergency with all the attendant risks
associated.
4.1. Palliation of Symptomatic Vertebral Metastasis Uncom-
plicated by MESCC. Pain is an emergency and needs to be
treated as such. Once the evaluation for MESCC has been
initiated, it is imperative that adequate analgesia be insti-
tuted. Pain is an emergency, but it is not a radiotherapeutic4 ISRN Surgery
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emergency. Proper and safe treatment planning for patients
with vertebral metastasis requires that the patient be able
to cooperate. Cooperation may be impossible if the patient
is in acute pain. Either the managing clinician or an
appropriatelyskilledconsultantshouldbecertainthatproper
pharmacologic management is instituted. It is often helpful
to have a rational and evidence-based approach to palliation.
Many professional societies have promulgated guidelines
[19] regarding relief of pain, but it still remains a pernicious
problem.
Even in a situation where radiotherapy is immediately
available, the average latency from delivery of treatment
to initiation of pain relief is approximately 2 weeks, and
maximum pain relief may not occur for a month or longer.
Adequate pharmacologic relief of pain must be provided at
the time of diagnosis and adequate arrangement made for
followup and titration of the medications as needed.
Probably the most overstudied problem in radiotherapy
is the palliation of pain from bone metastasis. Many high
quality prospective randomized trials have been performed
with many diﬀerent radiotherapy regimens. No protracted
treatment course has ever been found superior to single-
fraction (8Gy) radiotherapy. This is further reinforced by
the meta-analysis conducted by the Cochran Collaborative
[20]. The risk of developing MESCC or pathologic fracture
is not increased when comparing single fraction radiation to
a fractionated course. This was demonstrated in the British
Bone Pain Working Trial, which was designed with that end-
pointinmind[21].Itisinterestingtonotethatmultipletrials
have conﬁrmed, although there is no diﬀerence in palliationISRN Surgery 5
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of pain, that there is an increased use of repeat treatment
with the single-fraction regimens. Most feel retreatment
represents greater physician and patient acceptance of the
convenience of the single fraction regimen and willingness
to pursue further treatment for greater relief.
5. Summary
Vertebral metastasis represents a spectrum of clinical signif-
icance that should be systematically approached in order to
secure the optimal outcome for each patient. Rapid recog-
nition of the potentially devastating situation of MESCC
followed by prompt, evidence-based intervention results
in improved outcome for patients. Adequate pain relief
initiated by pharmacologic intervention and followed by
focal therapy minimizes suﬀering. Recognizing the special
situations in which surgical intervention or more advanced
radiotherapeutic techniques apply can have extraordinary
impact on select subsets of the patient population.
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